## VTRS: Viatris Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 2.2% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($10.55)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. VTRS LAWSUIT ALERT: Levi & Korsinsky Notifies Viatris Inc. Investors of a Class Action Lawsuit and Upcoming Deadline**
- Source: KSN.com | 20251206T080859 | Neutral | Relevance: 99%
-  Levi & Korsinsky LLP has announced a class action lawsuit against Viatris Inc. (NASDAQ:VTRS) for alleged securities fraud, seeking to recover losses for investors who bought shares between August 8, 2024, and February 26, 2025. The lawsuit claims Viatris misrepresented the impact of a failed FDA inspection of its Indore, India facility, causing a significant stock price drop after disappointing 2025 guidance was released. Investors affected are encouraged to learn about their rights to potential recovery.

**2. Viatris Inc. Stock Rises Friday, Outperforms Market**
- Source: 富途牛牛 | 20251208T160855 | Bullish | Relevance: 99%
- Viatris Inc. (VTRS) saw its stock rise on Friday, outperforming the market with a 2.10% increase. This news was published alongside Unity Software's Q4 earnings, which reported a 35% revenue increase year-over-year to $609 million, exceeding analyst estimates.

**3. Viatris Inc. (VTRS) Faces Investor Scrutiny After Possible Disclosure Delay About June 2024 FDA Inspection of Manufacturing Facility – Hagens Berman**
- Source: FOX 8 News | 20251208T070905 | Neutral | Relevance: 99%
- Hagens Berman is investigating Viatris Inc. (VTRS) for potential disclosure delays regarding a June 2024 FDA inspection of its Indore, India manufacturing facility. Investors suffered significant losses after Viatris disclosed an anticipated $500 million negative impact on revenues due to a December 2024 FDA determination, six months after the initial inspection that found deviations from Current Good Manufacturing Practice. The firm urges affected investors and individuals with relevant information to contact their attorneys.

**4. Viatris Inc Announces Agreement to Monetize Biocon Biologics Stake**
- Source: TradingView | 20251208T120848 | Somewhat-Bullish | Relevance: 98%
-  Viatris Inc announced an agreement to monetize its equity stake in Biocon Biologics for $815 million. This transaction will accelerate the expiration of the biosimilars non-compete clauses, ending it immediately ex-U.S. and in November 2026 in the U.S. The deal is expected to close in Q1 2026, pending conditions.

**5. Viatris Announces Agreement to Monetize its Equity Stake in Biocon Biologics Limited**
- Source: PR Newswire | 20251206T140216 | Bullish | Relevance: 98%
-  Viatris has announced a definitive agreement to sell its entire equity stake in Biocon Biologics Limited to its partner Biocon Limited for $815 million, comprising $400 million in cash and $415 million in Biocon equity shares. This transaction will accelerate the expiration of biosimilars non-compete restrictions, allowing Viatris to re-enter the biosimilars market globally, with immediate expiration for ex-U.S. markets and November 2026 for U.S. markets. The agreement is expected to close in Q1 2026, marking a strategic step in Viatris's evolution to build a diverse pharmaceutical portfolio.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 1 ($0.07M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 50.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 12.2% (-3.3%)
- Price (T.Rowe) Assoc: 7.3% (+6.7%)
- Blackrock Inc.: 7.1% (-1.1%)
- Davis Selected Advis: 6.0% (+4.5%)
- State Street Corpora: 4.8% (+0.8%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Momentum building: MRS_10 improving +3.0% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.14 indicates undervaluation relative to growth. Forward P/E 4.5x attractive for 7% earnings growth. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $12.8B |
| Beta | 0.83 |
| 52W Range | $6.85 - $13.13 |
| Short Interest | 2.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.14 |
| Forward P/E | 4.5 |
| Current P/E | 4.8 |
| YoY Growth | 6.9% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -0.8% to 2.2% (+3.0% in 5 days), confirming momentum buildup. Below STRENGTH zone by 0.8pp (needs >3.0% for momentum thesis). MRS_5 at 1.9% confirms short-term momentum alignment. Outperforming sector by 5.6pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 2.21% (CS: 76) | Neutral |
| RSI_14 | 63.6 | Neutral |
| MACD Histogram | 0.03 | Bullish |
| vs SMA20 | 1.037x | Above |
| vs SMA50 | 1.068x | Above |
| vs SMA200 | 1.171x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $11.09
- **Stop Loss:** $10.55 (4.9% risk)
- **Target:** $11.63 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 925
- **Position Value:** $10,258.25
- **Portfolio %:** 10.26%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

### Earnings

**Next:** 2026-02-26 (Est: $0.53)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.62 | $0.67 | +8.5% |
| 2025Q2 | $0.56 | $0.62 | +11.6% |
| 2025Q1 | $0.49 | $0.50 | +1.6% |
| 2024Q4 | $0.57 | $0.54 | -5.6% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*